CLSD Relative Valuation
CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLSD is overvalued; if below, it's undervalued.
Historical Valuation
Clearside Biomedical Inc (CLSD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.48 is considered Undervalued compared with the five-year average of -11.29. The fair price of Clearside Biomedical Inc (CLSD) is between 2.45 to 8.75 according to relative valuation methord. Compared to the current price of 0.35 USD , Clearside Biomedical Inc is Undervalued By 85.68%.
Relative Value
Fair Zone
2.45-8.75
Current Price：0.35
85.68%
Undervalued
-0.12
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Clearside Biomedical Inc. (CLSD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -1.82, Undervalued between -1.82 and -0.76, Fairly Valued between 1.37 and -0.76, Overvalued between 1.37 and 2.43, and Strongly Overvalued above 2.43. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.12
EV/EBIT
Clearside Biomedical Inc. (CLSD) has a current EV/EBIT of -2.12. The 5-year average EV/EBIT is -0.19. The thresholds are as follows: Strongly Undervalued below -54.41, Undervalued between -54.41 and -27.30, Fairly Valued between 26.91 and -27.30, Overvalued between 26.91 and 54.02, and Strongly Overvalued above 54.02. The current Forward EV/EBIT of -2.12 falls within the Historic Trend Line -Fairly Valued range.
3.48
PS
Clearside Biomedical Inc. (CLSD) has a current PS of 3.48. The 5-year average PS is 109.99. The thresholds are as follows: Strongly Undervalued below -119.96, Undervalued between -119.96 and -4.98, Fairly Valued between 224.96 and -4.98, Overvalued between 224.96 and 339.94, and Strongly Overvalued above 339.94. The current Forward PS of 3.48 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Clearside Biomedical Inc. (CLSD) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.05. The thresholds are as follows: Strongly Undervalued below -23.47, Undervalued between -23.47 and -14.26, Fairly Valued between 4.15 and -14.26, Overvalued between 4.15 and 13.36, and Strongly Overvalued above 13.36. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Clearside Biomedical Inc. (CLSD) has a current P/FCF of 0.00. The 5-year average P/FCF is 26.32. The thresholds are as follows: Strongly Undervalued below -105.54, Undervalued between -105.54 and -39.61, Fairly Valued between 92.25 and -39.61, Overvalued between 92.25 and 158.19, and Strongly Overvalued above 158.19. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Clearside Biomedical Inc (CLSD) has a current Price-to-Book (P/B) ratio of -0.04. Compared to its 3-year average P/B ratio of -0.25 , the current P/B ratio is approximately -83.94% higher. Relative to its 5-year average P/B ratio of 3.85, the current P/B ratio is about -101.03% higher. Clearside Biomedical Inc (CLSD) has a Forward Free Cash Flow (FCF) yield of approximately -1013.36%. Compared to its 3-year average FCF yield of -39.24%, the current FCF yield is approximately 2482.25% lower. Relative to its 5-year average FCF yield of -25.64% , the current FCF yield is about 3851.85% lower.
-0.04
P/B
Median3y
-0.25
Median5y
3.85
-1013.36
FCF Yield
Median3y
-39.24
Median5y
-25.64
Competitors Valuation Multiple
The average P/S ratio for CLSD's competitors is 0.00, providing a benchmark for relative valuation. Clearside Biomedical Inc Corp (CLSD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -80.64%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CLSD decreased by 97.12% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -740.66 to -2.97K.
The secondary factor is the Revenue Growth, contributed -80.64%to the performance.
Overall, the performance of CLSD in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Clearside Biomedical Inc (CLSD) currently overvalued or undervalued?
What is Clearside Biomedical Inc (CLSD) fair value?
How does CLSD's valuation metrics compare to the industry average?
What is the current P/B ratio for Clearside Biomedical Inc (CLSD) as of Dec 05 2025?
What is the current FCF Yield for Clearside Biomedical Inc (CLSD) as of Dec 05 2025?
What is the current Forward P/E ratio for Clearside Biomedical Inc (CLSD) as of Dec 05 2025?